Telemark Asset Management LLC Purchases 100,000 Shares of Cellebrite DI Ltd. $CLBT

Telemark Asset Management LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 20.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 600,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Telemark Asset Management LLC owned 0.25% of Cellebrite DI worth $11,118,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of CLBT. Financial Management Professionals Inc. bought a new position in shares of Cellebrite DI in the third quarter worth approximately $28,000. CWM LLC raised its holdings in Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Cellebrite DI by 1,998.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares in the last quarter. Toth Financial Advisory Corp bought a new position in Cellebrite DI in the 3rd quarter valued at approximately $38,000. Finally, Pacer Advisors Inc. boosted its stake in Cellebrite DI by 523.4% during the 3rd quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock valued at $51,000 after purchasing an additional 2,303 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CLBT. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Lake Street Capital upped their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Bank of America increased their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Down 4.5%

Cellebrite DI stock opened at $13.16 on Friday. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $20.86. The company has a market cap of $3.15 billion, a P/E ratio of 42.45, a P/E/G ratio of 2.02 and a beta of 1.28. The business has a 50-day simple moving average of $16.59 and a two-hundred day simple moving average of $17.01.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. Research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.